University Hospital Of Montpellier
- Address
- 191 Avenue Du Doyen Gaston Giraud, 34295 Montpellier, France
Respiratory Tract Diseases
The University Hospital Of Montpellier is conducting advanced research on Chronic Obstructive Pulmonary Disease, focusing on the long‑term safety and tolerability of innovative therapies such as itepekimab. Trials aim to monitor late‑onset adverse events and assess how gene‑modified cells may impact disease progression.
- Long‑term safety monitoring of inhaled and systemic agents
- Evaluation of severe adverse events including infections and new malignancies
- Growth and sexual maturity assessment in pediatric subjects receiving cellular therapies
With 22 investigators on site, the department leverages its respiratory expertise to improve outcomes for patients with moderate to severe COPD across Europe.
Neoplasms
Studies at the service target Solid and Hematological Malignancies, offering open‑label access to therapies like VRDN-001 for participants who previously did not respond. The goal is to evaluate both safety and efficacy, aiming to expand treatment options for difficult‑to‑treat cancers.
- Open‑label extension for non‑responders after pivotal trials
- Safety and efficacy assessment of novel biologics in cancer patients
- Integration of cellular and antibody‑based treatments in oncology protocols
The multidisciplinary team collaborates with national oncology networks, reinforcing the hospital’s role in cutting‑edge cancer research.
Eye Diseases
The department also investigates Thyroid eye disease within the broader context of autoimmune ocular disorders. Long‑term follow‑up studies track the incidence of neurological and autoimmune adverse events after administration of gene‑modified cells, seeking to improve diagnostic and therapeutic strategies for eye conditions.
- Surveillance of late‑onset neurological and autoimmune events
- Assessment of ocular outcomes following cellular therapy
- Development of biomarkers for disease activity and treatment response
By integrating ophthalmology expertise with advanced immunology, the site contributes valuable insights to the management of complex eye diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Hospital Of Montpellier
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Long-term Follow-up of Gene-Modified Cell Therapy with Brexucabtagene Autoleucel and Axicabtagene Ciloleucel in Solid and Hematological Malignancies | Kite Pharma Inc. | Phase II | Recruiting | Nov 2022 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol | 1 | Unknown | 2024-09-10 | 2024-09-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.